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RecentstudiessuggestthatALDH1isaputativemarkerforHNSCC-derivedcancerstemcells.However,theregulationmechanisms
that maintain the stemness and metastatic capability of HNSCC-ALDH1+ cells remain unclear. Initially, HNSCC-ALDH1+ cells
from HNSCC patient showed cancer stemness properties, and high expression of Bmi1 and Snail. Functionally, tumorigenic
properties of HNSCC-ALDH1+ cells could be downregulated by knockdown of Bmi-1. Overexpression of Bmi-1 altered in
expression property ALDH1− cells to that of ALDH1+ cells. Furthermore, knockdown of Bmi-1 enhanced the radiosensitivity of
radiation-treated HNSCC-ALDH1+ cells. Moreover, overexpression of Bmi-1 in HNSCC-ALDH1− cells increased tumor volume
and number of pulmonary metastatic lesions by xenotransplant assay. Importantly, knock-down of Bmi1 in HNSCC-ALDH1+
cells signiﬁcantly decreased distant metastases in the lungs. Clinically, coexpression of Bmi-1/Snail/ALDH1 predicted the worst
prognosis in HNSCC patients. Collectively, our data suggested that Bmi-1 plays a key role in regulating Snail expression and
cancer stemness properties of HNSCC-ALDH1+ cells.
1.Introduction
Head and neck squamous cell carcinoma (HNSCC), includ-
ing oral squamous cell carcinoma (OSCC), is the sixth most
prevalent type of malignancy worldwide and accounts for
approximately 8% to 10% of all cancers in Southeast Asia
[1, 2]. HNSCC-related mortality is mainly caused by cervical
lymph node metastasis, and occasionally by distant organ
metastasis [3].
The epithelial-mesenchymal transition (EMT) is a pro-
cess in which epithelial cells lose their polarity and adopt a
mesenchymal phenotype [4]. This process is thought to be a
critical step in the induction of tumor metastasis and malig-
nancy [5]. Mani et al. demonstrated that induction of EMT
results in cells that have stem cell properties and generates
cells with properties similar to breast cancer stem cells [6].
Snail,amemberofthezinc-ﬁngertranscriptionfactorfamily,
isoneofthemasterregulatorsthatpromotesEMTandmedi-
ates invasiveness as well as metastasis in many diﬀerent types
of malignant tumors [7, 8]. The aldehyde dehydrogenase
(ALDH) family of enzymes is comprised of cytosolic isoen-
zymes that oxidize intracellular aldehydes and contribute
to the oxidation of retinol to retinoic acid in early stem
cell diﬀerentiation [9]. Recently, ALDH has been reported
to be a unique marker of head and neck cancer stem cells
(CSC) [10, 11]. ALDH1 was also found to co-localize with
other CSCs-related markers, including MMP-9, CD44, and
CK14, at the invasive front of the tumor [12]. We previously2 Journal of Oncology
Table 1: Case description, tumorigenic characteristics and treatment eﬀects of ALDH1+ and ALDH1− HNSCC.
Number of cells injected
Case Age/Sex ALDH+ (%) Spheres Parental ALDH1+ ALDH1+ (Sh-Bmi 1) ALDH1− ALDH1− (Bmi 1Over)
Formation
1 71/ M 44.2 Yes 1,000 (0/3) 1,000 (1/3) 1,000 (0/3) 1,000 (0/3) 1,000 (1/3)
3,000 (0/3) 3,000 (3/3) 3,000 (0/3) 3,000 (0/3) 3,000 (1/3)
10,000 (1/3) 10,000 (3/3) 10,000 (2/3) 10,000 (1/3) 10,000 (2/3)
2 73/ F 24.7 Yes 1,000 (0/3) 1,000 (1/3) 1,000 (1/3) 1,000 (0/3) 1,000 (0/3)
3,000 (0/3) 3,000 (2/3) 3,000 (2/3) 3,000 (0/3) 3,000 (1/3)
10,000 (2/3) 10,000 (2/3) 10,000 (2/3) 10,000 (0/3) 10,000 (2/3)
3 61 / F 8.6 Yes 1,000 (0/3) 1,000 (1/3) 1,000 (1/3) 1,000 (0/3) 1,000 (0/3)
3,000 (0/3) 3,000 (3/3) 3,000 (1/3) 3,000 (0/3) 3,000 (2/3)
10,000 (0/3) 10,000 (3/3) 10,000 (2/3) 10,000 (0/3) 10,000 (3/3)
4 71 / M 1.2 Yes 1,000 (0/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3)
3,000 (0/3) 3,000 (3/3) 3,000 (0/3) 3,000 (0/3) 3,000 (2/3)
10,000 (0/3) 10,000 (3/3) 10,000 (2/3) 10,000 (0/3) 10,000 (3/3)
5 69 / M 19.2 Yes 1,000 (0/3) 1,000 (1/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3)
3,000 (0/3) 3,000 (3/3) 3,000 (1/3) 3,000 (0/3) 3,000 (2/3)
10,000 (1/3) 10,000 (3/3) 10,000 (2/3) 10,000 (0/3) 10,000 (3/3)
6 72 / M 5.5 Yes 1,000 (0/3) 1,000 (1/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3)
3,000 (0/3) 3,000 (3/3) 3,000 (1/3) 3,000 (0/3) 3,000 (2/3)
10,000 (0/3) 10,000 (3/3) 10,000 (1/3) 10,000 (0/3) 10,000 (2/3)
ALDH1+: ALDH1-positive HNSCC cells; ALDH1−: ALDH1-negative HNSCC cells.
ALDH1+ or ALDH1+cells were injected into neck of SCID mice.
reported the isolation of ALDH1-positive cells from patients
with HNSCC [13]. These HNSCC-ALDH1+ cells displayed
the radioresistance and represented a reservoir of cells that
have the proliferative potential to generate tumors [13].
ALDH1+-lineage cells underwent EMT and endogenously
co-expressed Snail [13]. These ﬁndings suggested that Snail
expressionmayregulatethetumorigenesis,radiochemoresis-
tance, and cancer stem cell properties of malignant HNSCC
tumors [13]. However, the molecular mechanisms involved
in mediating metastasis and tumor malignancy of HNSCC-
CSC through the regulation of Snail remain unknown.
Bmi-1 is a member of the Polycomb (PcG) family of
transcriptional repressors that mediate gene silencing by
regulating chromatin structure [14]. Bmi-1 is essential for
maintaining the ability of neural, hematopoietic, and intesti-
nal stem cells to self-renew [15–17]. Bmi-1 was identiﬁed
as a proto-oncogene that cooperates with MYC to promote
the generation of lymphoma [18]. Bmi-1 also inhibited
MYC-induced apoptosis by repressing the Cdkn2a locus
[19]. Additionally, Bmi-1 has been veriﬁed as a predictor
of prognosis in bladder cancer [20], prostate cancer [21],
brain cancer [22, 23], breast cancer [24], pancreatic cancer
[25], and lung cancer [26]. Bmi-1 has been demonstrated to
play a role in the tumorigenesis of HNSCC [27, 28]. Bmi-1
has also been reported to be involved in tumor metastasis
[29, 30]. Recently, an elegant study by Song et al. showed
that Bmi-1 can directly promote EMT and malignancy in
nasopharyngeal carcinoma by regulating Snail [31]. The goal
of this study was to clarify the relationship between Bmi-1,
Snail, and ALDH1 in HNSCC or HNSCC-associated CSC
and the involved molecular mechanisms.
2.MaterialsandMethods
2.1. Isolation and Cultivation of HNSCC-Derived ALDH1+
and ALDH1− Cells from HNSCC Patients. This study fol-
lowed the tenets of the Declaration of Helsinki. All samples
were obtained after patients provided informed consent. The
study was approved by the Institutional Ethics Commit-
tee/Institutional Review Board of Taipei Veterans General
Hospital. The information of HNSCC patients has been
previously described in Table 1. The dissociated cells from
the samples of HNSCC patients were suspended at 1 ×
106 cells/mL in 37
◦C DMEM supplemented with 2% FCS.
The identiﬁcation of aldehyde dehydrogenase 1 (ALDH1)
positive HNSCC cells was carried out using the Aldeﬂuor
assay (StemCell Technologies, Durham, NC, USA) and
ﬂuorescence-activated cell sorting. Cells were suspended
in ALDEFLUOR assay buﬀer containing ALDH substrate
(BAAA, 1μmol/l per 1 × 106 cells) and incubated for
40 min at 37
◦C. As a negative control, for each sample
of cells, an aliquot was treated with 50mmol/l diethy-
laminobenzaldehyde (DEAB), a speciﬁc ALDH inhibitor.
Thesortinggateswereestablishedusingthecellsstainedwith
PI only as a negative control; the ALDEFLUOR-stained cells
treated with DEAB and staining with a secondary antibody
alone to test for viability. HNSCC-ALDH1+ cells were
cultured in a medium consisting of serum-free DMEM/F12Journal of Oncology 3
Table 2: The sequences for the primers of quantitative RT-PCR.
Gene(Accession No.) Primer Sequence (5  to 3 ) Product size (bp) Tm (◦C)
Oct-4(NM 002701) F: GTGGAGAGCAACTCCGATG 86 60
R: TGCTCCAGCTTCTCCTTCTC
Nanog(NM 024865) F: ATTCAGGACAGCCCTGATTCTTC 76 60
R: TTTTTGCGACACTCTTCTCTGC
SOX-2(NM 003106) F: CGAGTGGAAACTTTTGTCGGA 74 60
R: TGTGCAGCGCTCGCAG
Musashi(NM 002442) F: TCCCTCGGCGAGCACA 64 60
R: GACAGCCCCCCCACAAA
c-Myc(NM 002467) F: GGAACGAGCTAAAACGGAGCT 71 55
R: GGCCTTTTCATTGTTTTCCAACT
β-catenin(NM 001904) F: CCAGCCGACACCAAGAAG 130 55
R: CGAATCAATCCAACAGTAGCC
Bmi1(NM 005180) F?AAATGCTGGAGAACTGGAAAG 124 50
R?CTGTGGATGAGGAGACTGC
Nestin(NM 006617) F: AGGAGGAGTTGGGTTCTG 112 50
R: GGAGTGGAGTCTGGAAGG
Snail(NM 005985) F:GCTGCCAATGCTCATCTGGGACTCT 300 55
R: TTGAAGGGCTTTCGAGCCTGGAGAT
Slug(NM 003068) F: GTGATTATTTCCCCGTATCTCTAT 292 50
R: CAATGGCATGGGGGTCTGAAAG
MDR-1 (NM 000927) F: TGGCAAAGAAATAAAGCGACTGA 76 60
R: CAGGATGGGCTCCTGGG
MRP-1(X60111) F: GCTTCCTCTTGGTGATATTCG 176 50
R: GCAGTTCAACGCATAGTGG
ABCG2(NM 004827) F: CATGTACTGGCGAAGAATATTTGGT 74 60
R: CACGTGATTCTTCCACAAGCC
GAPDH(NM 002046) F: CATCATCCCTGCCTCTACTG 180 60
R: GCCTGCTTCACCACCTTC
(Gibco-BRL, Gaithersburg, MD), N2 supplement (R and
D Systems Inc., Minneapolis), 10ng/mL bFGF (R and D
Systems), and 10ng/mL EGF (R and D Systems) [13, 32].
2.2. Quantitative Real-Time RT-PCR. Brieﬂy, total RNA
(1μg) of each sample was reverse-transcribed using 0.5μg
oligo dT and 200 U Superscript II RT (Invitrogen). The
primer sequences for real-time RT-PCR were listed in
Table 2. The ampliﬁcation was carried out in a total
volume of 20μL containing 0.5μmol·L−1 of each primer,
4mmol·L−1 MgCl2, 2μL LightCyclerTM-FastStart DNA
Master SYBR green I (Roche Molecular Systems, Alameda,
CA), and 2μL of 1:10 diluted cDNA. PCR reactions were
prepared in duplicate and performed using the follow-
ing program: 95
◦C for 10min, followed by 40 cycles of
denaturation at 95
◦C for 10 sec, annealing at 55
◦Cf o r
5 sec, and extension at 72
◦C for 20 sec. Standard curves
(cycle threshold values versus template concentration) were
prepared for each target gene and for the endogenous
reference gene (GAPDH) for each sample. Quantiﬁcation of
unknown samples was performed using LightCycler Relative
Quantiﬁcation Software version 3.3 (Roche).
2.3. Knockdown and Overexpression of Bmi-1 with Lentivirus.
The pLVRNAi vector was purchased from Biosettia Inc.
(Biosettia, San Diego CA). The oligonucleotide 5 -AAA-
ACCTAATACTTTCCAGATTGATTTGGATCCAAATCA-
ATCTGGAAAGTATTAGG-3  targeting human Bmi-1
(NM 005180, nt 1061–1081) was synthesized and cloned
into pLVRNAi to generate the lentiviral expression vector,
pLVRNAi/sh-Bmi1. The lentiviral expression vector carrying
Bmi-1 full-length cDNA, pLV/Bmi-1 was obtained from
Biosettia Inc. pCMVΔR8.9 and pMD.G, expressing GAG-
POL and the vesicular stomatitis virus envelope, respectively,
were provided by the consortium (Academia Sinica, Taipei,
Taiwan). The lentiviruses were generated by cotransfecting4 Journal of Oncology
5 × 106 293FT cells per 10cm plate with lentiviral vector
and packaging plasmids using Lipofectamine 2000 (LF2000,
Invitrogen). Supernatants were collected 48 hours after
transfection and ﬁltered. The 48-hour posttransduction viral
titers were determined by FACS. Subconﬂuent cells were
infected with lentivirus at a multiplicity of infection of
5 in the presence of 8μg/mL polybrene (Sigma-Aldrich)
[13, 33].
2.4. Microarray Analysis and Bioinformatics. Total RNA was
extracted from cells using Trizol reagent (Life Technologies,
Bethesda, MD, USA) and the Qiagen RNAeasy (Qiagen,
Valencia, CA, USA) column for puriﬁcation. Aﬀymetrix HG
U133 Plus 2.0 microarrays containing 54,675 probe sets for
>47,000 transcripts and variants, including 38,500 human
genes. A typical probeset contains eleven 25-mer oligo
nucleotide pairs (a perfect match and a mismatch control).
For microarray analysis, sample labeling, hybridization, and
staining were carried out by Aﬀymetrix standard protocol
with aﬀyQCReport. Probeset was normalized with loess
method of all microarrays. The average linkage distance was
used to assess the similarity between two groups of gene
expression proﬁles as described below. The diﬀerence in
distance between two groups of sample expression proﬁles
to a third was assessed by comparing the corresponding
average linkage distances (the mean of all pairwise distances
(linkages) between members of the two groups concerned).
The error of such a comparison was estimated by combining
the standard errors (the standard deviation of pairwise
linkages divided by the square root of the number of
linkages) of the average linkage distances involved. Classi-
cal multidimensional scaling (MDS) was performed using
the standard function of the R program to provide a
visual impression of how the various sample groups are
related.
2.5. In Vivo Tumor Growth and Metastasis. All procedures
involving animals were in accordance with the institu-
tional animal welfare guidelines of Taipei Veterans General
Hospital. Eight-week-old SCID mice and/or nude mice
(BALB/c strain) were injected with 105 cells orthotopically.
In vivo GFP imaging was performed using an illuminating
device (LT-9500 Illumatool/TLS equipped with an excitation
source (470nm) and ﬁlter plate (515nm)). Tumor size was
measured with calipers and the tumor volume was calculated
using the formula (Length × Width2)/2. The integrated
optical density of green ﬂuorescence intensity was captured
and analyzed using Image Pro-plus software [33, 34].
2.6. Statistical Analysis. The Statistical Package of Social
Sciences software (SPSS, Inc., Chicago, IL) was used for
statistical analysis. An independent Student’s t-test was
used to compare the continuous variables between groups.
The Kaplan-Meier procedure was used to calculate survival
probability estimates. A log-rank test was used to compare
thecumulativesurvivaldurationsindiﬀerentpatientgroups.
The statistical signiﬁcance level was set at 0.05 for all tests.
3. Results
3.1. HNSCC-Derived ALDH1-Positive Cells Displayed
Tumorigenic and Stemness Properties. Initially, parental,
isolated ALDH1+, and ALDH1− cells were isolated
from tissue samples of six HNSCC patients using the
Aldeﬂuor assay and the ﬂuorescence-activated cell sorting
(FACS) analysis (Figure 1(a) and Table 1)[ 13, 35]. It
has been reported that cancer stem-like cells can be
cultured in suspension to generate ﬂoating spheroid-
like bodies (SB) under serum-free medium with bFGF
and EGF [36]. Interestingly, ALDH1+ increased higher
tumor spheres-forming capability than that of ALDH1−
(Figure 1(b)). Furthermore, ALDH1+-derived spheres
with regular 10% serum cultivation increased epithelial-
attached cells and diﬀerentiation marker (CK18)(See Figure
1(a) in supplementary material available online at doi:
10.1155/2011/609259). To evaluate the enhancement of
tumorigenicity of HNSCC-ALDH1+ cells, soft agar colony
formation assays and Matrigel/Transwell-invasion and were
examined. Compared with parental and ALDH1−, ALDH1+
derived from HNSCC Patients no. 1 and no. 2 showed
colony-forming ability and higher invasion activity (Figures
1(c) and 1(d)). To evaluate the in vivo tumor initiating
capability of ALDH1+ and ALDH1−, we injected 1000,
3000, and 104 cells into the neck of SCID mice. The results
showed that 104 ALDH1− did not induce tumor formation
but 3,000 ALDH1+ from the HNSCC tissues of six patients
in xenotransplanted mice all resulted in the generation
o fv i s i b l et u m o r s6w e e k sa f t e ri n j e c t i o n( T a b l e1). The
results of xenotransplanted analysis further showed that
ALDH1+ demonstrated higher abilities to induce tumor
growth (Figure 1(e)). Lastly, serial xenotransplanted analysis
suggested that ALDH1+ had in vivo self-renewal ability
(Supplementary Figure 1(b)). Based on these ﬁndings,
the ALDH1+-lineage cells isolated from HNSCC patients
presented the signiﬁcant tumor-initiating abilities, especially
inALDH1+ cellsfrompatientsno.1andno.2.Real-timeRT-
PCR data demonstrated that the stemness and EMT-related
genes (especially in Bmi-1 and Snail) were signiﬁcantly
activated in HNSCC ALDH1+ (Table 2 and data not
shown).
3.2. Knockdown of Bmi-1 in HNSCC-ALDH1+ Cells Down-
Regulates Snail and Lessens in vitro Tumorigenicity. To
further investigate the role of Bmi-1 in maintaining the
biological properties of HNSCC-ALDH1+,w eu s e da
loss-of-function approach, in which Bmi-1 was knocked
down by small hairpin RNA (shRNA) in HNSCC-ALDH1+
cells. Stable knockdown of Bmi-1 in HNSCC-ALDH1+
cells was achieved by transduction with lentivirus that
expressed shRNA targeting Bmi-1 (sh-Bmi-1). Lentivirus
that expressed shRNA targeted against luciferase (sh-Luc.)
was used as a control. Western blot analysis conﬁrmed that
shBmi-1 repressed Bmi-1 protein expression in HNSCC-
ALDH1+ cells (Figure 2(a)). Importantly, silencing Bmi-1
expression led to downregulation of Snail and ALDH1
expression (Figure 2(a)). Additionally, our results showed
that silencing of Bmi-1 in HNSCC-ALDH1+ cells inhibitedJournal of Oncology 5
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Figure 1: Isolation and Characterization of HNSCC-derived ALDH1-positive Cells. (a) Analyzing and sorting ALDH1+-positive and
ALDH1−-negative from HNSCC tissues via FACScan. DEAB, an inhibitor of ALDH1, was used for negative control. (b) Evaluation of sphere
body formation in the parental cells, ALDH1− cells, and ALDH1+cells. Sphere bodies were counted after 1 week. The numbers of resultant
colonies (c) and invasion cells (d) from parental cells, ALDH1+ cells, and ALDH1−cells were counted in vitro. (e) Macroscopic features of
cells in a nude mouse at 6 weeks after xenotransplantation. Blue arrow indicates the site of injection of ALDH1−cells. Red arrow indicates
the site of injection of ALDH1+cells. Yellow arrow indicates the site of injection of ALDH1+cells. ∗P<. 0 5 .D a t as h o w nh e r ea r et h em e a n±
SD of three experiments.
the ability of the cells to form colonies on soft agar
(Figure 2(b)) and migrate/invade (Figure 2(c)).
3.3. Overexpression of Bmi-1 in HNSCC-ALDH1− Cells
Enhances Tumorigenic Properties by Upregulating Snail. To
evaluate whether overexpression of Bmi-1 could enhance the
tumorigenic properties of HNSCC-ALDH1− cells, we gen-
erated stable Bmi-1-overexpressing (Bmi-1Over) HNSCCs
using lentiviral transduction (Figure 2(d)). Total proteins
from HNSCC-ALDH1− overexpressing Bmi-1 exhibited
elevated expression of Snail and ALDH1 (Figure 2(d)). In
addition,overexpressionofBmi-1signiﬁcantlyincreasedsoft
agar colony formation (Figure 2(e)), and migration/invasion
of HNSCC-ALDH− cells (Figure 2(f)). Taken together, our
resultssuggestthatBmi-1modulatestheinvitrotumorigenic
properties in HNSCC-ALDH1+ or ALDH1− cells by regulat-
ing Snail.
3.4. Overexpression of Bmi-1 in HNSCC-ALDH1− Cells Pro-
motes Stemness Properties. To explore molecules governing
stemness and tumorigenicity in HNSCC-CD44−ALDH1−
cells treated with Bmi1-overexpressing lentivirus, we exam-
ined their transcriptome proﬁle using gene expression
microarrayanalysis(Figure3(a)).Principlecomponentanal-
ysis (PCA) further showed that the transcriptome proﬁle of
HNSCC-ALDH1− cells overexpressing Bmi-1 demonstrated
higher expression levels of embryonic stem cells (ESCs)
transcriptomes (Table 3 and Figure 3(b)). Multidimensional6 Journal of Oncology
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Figure 2: Overexpression of Bmi-1 in HNSCC-ALDH1− cells or knockdown of Bmi-1 in HNSCC-ALDH+ cells modulates Snail expression
and tumorigenicity in vitro. (a) Down-regulation of Bmi-1 mediated by lentiviral shRNA and expression of Snail and ALDH1 in HNSCC-
ALDH1+ cells was analyzed by western blot. Colony formation (b) and migration/invasion ability (c) of shLuc.-expressing and shBmi-1-
expressing HNSCC-ALDH1+cells was determined. (d) Total protein was prepared from control GFP–expressing andBmi-1-overexpressing
HNSCC-ALDH1− cells and analyzed by immunoblotting with anti-Bmi-1, anti-Snail, anti-ALDH1, or anti-GAPDH antibodies as indicated.
The amount of GAPDH protein from each crude cell extract was used as loading control. Colony formation (e) and migration/invasion
ability (f) of Bmi-1-overexpressing and control-GFP-expressing HNSCC-ALDH1− were analyzed. ∗P<. 05. Data shown here are the mean
± SD of three experiments.
scaling analysis furtherdemonstrated that HNSCC-ALDH1+
cells and HNSCC-ALDH1− cells overexpressing Bmi-1 are
moresimilartoESCsthanHNSCC-ALDH1− cells( ∗P <. 05;
Figure 3(c)). To validate the microarray analysis results, real-
time PCR was performed to conﬁrm that the mRNA expres-
sion levels of the embryonic genes (Oct-4, Nanog, Sox2,
KLF4, and Lin28), EMT-related genes (Snail and Slug), and
drug-resistant-relatedgenes(MDR-1andABCG2)inBmi-1-
overexpressing ALDH1− cells were signiﬁcantly higher than
those in ALDH1− cells (
∗P <. 05; Table 2 and Figure 3(d)).
3.5. Elevation of In Vivo Tumor Growth, Metastatic Activity,
and Radioresistance in HNSCC-ALDH1− Cells by Overex-
pression of Bmi-1. We next sought to determine if Bmi-
1 expression could modulate the in vivo tumor initiating
activity in immunocompromised nude mice. To monitor
the in vivo growth of ALDH1+, ALDH1−, and Bmi-1-
overexpressing ALDH1− cells, these cells were transfected
using a lentivector combined with the green ﬂuorescent
protein gene (GFP) and followed by in vivo GFP imaging
system. Firstly, the results showed that 1 × 104ALDH1−
cells did not induce tumor formation in nude mice, but
1000 ALDH1+ cells generated visible tumors 6 weeks after
injection (Table 1). In contrast to ALDH1− cells, one of three
(33.3%) nude mice was detected with the tumor formation
after 6-week transplantation of 3000 Bmi-1-overexpressing
ALDH1− cells. Furthermore, tumor volumes in HNSCC-
ALDH1+ transplanted mice were signiﬁcantly decreased
whenmiceweretreatedwithsh-Bmi-1(Table1;Figure4(a)).
Overexpression of Bmi-1 enhanced in vivo tumor growthJournal of Oncology 7
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Figure 3: Stemness properties were enhanced in HNSCC-ALDH1− cells when Bmi-1 was overexpressed. (a) Gene expression microarray
analysis (Gene tree) for altered genes diﬀerentially expressed in Bmi-1-overexpressing HNSCC-ALDH1− cells compared to HNSCC-
ALDH1− cells by a hierarchy heat map. The time dependent changes of altered genes are presented on a log scale of expression values
provided by GeneSpring GX software. (b) Principle component analysis (PCA) demonstrated that overexpression of Bmi-1 in HNSCC-
ALDH1− cells could enhance the gene signature of embryonic stem cells (ESCs) in HNSCC-ALDH1− cells. (c) Multidimensional scaling
analysis.AveragelineagetranscriptomedistancesbetweenHNSCC-ALDH1+,HNSCC-ALDH1−,HNSCC-ALDH1+/sh-Bmi-1,andHNSCC-
ALDH1−/Bmi1over cells. ∗P<. 05.(d)TranscriptsofOct-4,Nanog,Sox2,KLF4,Lin28,Snail,Slug,MDR-1,andABCG2inHNSCC-ALDH1−
and HNSCC-ALDH1−/Bmi-1over cells (∗P<. 05: ALDH1− versus Bmi-1-overexpressing ALDH1−).
in HNSCC-ALDH1− (Table 1; Figure 4(a)). Furthermore,
we investigated the role of Bmi-1 in the radio sensitivity
of HNSCC-ALDH1− and HNSCC-ALDH1+ treated with
sh-Bmi-1 and Bmi-1 overexpressing. An ionizing radiation
(IR) dose of 0 to 10Gy was applied to these cells, and
HNSCC-ALDH1+ cells showed greater radioresistance than
the ALDH1− cells (P<. 05; Figure 4(b)). Knockdown
of BMI-1 in ALDH1+ cells results in signiﬁcant inhibi-
tion of radioresistance while overexpression of BMI-1 in
ALDH- cells promotes radioresistant properties (P<. 05;8 Journal of Oncology
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Figure 4: Determination of the role of Bmi-1 on in vivo tumor growth and radioresistance in HNSCC-ALDH1+cells. (a) Tumor volume
was measured after injection of either HNSCC-ALDH1+, sh-Bmi-1 treated HNSCC-ALDH1+, HNSCC-ALDH1−, or Bmi-1-overexpressing
HNSCC- ALDH1− cells into the neck of SCID mice. Error bars correspond to SD. (b) To determine the radiation eﬀect on the cell survival
rate, an ionizing radiation (IR) dose from 0 to 10Gy was used to treated with ALDH1+/vector, ALDH1+/sh-Bmi-1, ALDH1− /vector, or
Bmi-1-overexpressing HNSCC- ALDH1− HNSCC cells.
Figure 4(b)). Moreover, to conﬁrm that Bmi-1 is crucial
for metastasis in vivo, mice were injected with diﬀerent
numbers of ALDH1+, ALDH1+/sh-Bmi-1, ALDH1−/Bmi-
1over or control GFP-expressing ALDH1− cells. 5x105 Bmi-
1-overexpressing ALDH1− cells signiﬁcantly increased local
invasion, distant metastasis to the lungs and tumor size com-
pared with control ALDH1− cells (Figures 5(a) and 5(b)).
In addition, silencing Bmi-1 in ALDH1+ cells eﬀectively
reduced the number of lung metastases and tumor size in
vivo (Figures 5(a) and 5(b)). Taken together, our results
reveal a crucial role for Bmi-1 signaling in the maintenance
ofinvivotumorigenicityandmetastasisofHNSCC-ALDH1+
and -ALDH1− cells.
3.6. Coexpression of Bmi-1, Snail, and ALDH1 in HNSCC
Tissues Correlates with Poor Overall Survival Rate of HNSCC
Patients. Elevated Snail protein expression in HNSCC is
correlated with the development of metastasis and poor
survival [37]. Elevated expression of ALDH1 also correlates
with poor prognosis for HNSCC patients [13]. To investigate
whether there is a positive correlation between Bmi-1, Snail,
and ALDH1 in head and neck cancers, we studied the
expression of Bmi-1, Snail, and ALDH1 by immunohisto-
chemical (IHC) staining of a panel of specimens array from
93 HNSCC patients. The IHC results showed that elevated
expression of Bmi-1, Snail, and ALDH1 was positively
associated with high-grade, poorly diﬀerentiated HNSCC
(Figure 6(a)). Our results also showed a signiﬁcant positive
correlation between ALDH-1, Bmi-1 (Figure 6(b)); ALDH-
1 and Snail (Figure 6(c)); Bmi-1 and Snail (Figure 6(d))i n
HNSCC tissues. This is consistent with previous studies that
reported that HNSCC-ALDH1+ cells have elevated Bmi-1
and Snail expression [13, 38]. To determine the prognostic
signiﬁcance of Bmi-1, Snail, and ALDH1 coexpression in
patients with HNSCC, Kaplan-Meier survival analysis was
performed. Patients who were triple positive for Bmi-1,
Snail, and ALDH1 were predicted to have the worst survival
rate compared with other head and neck cancer patients
(Figure 6(e);B m i - 1 +/Snail+/ALDH1+ versus other groups).
Overall, these data indicate that expression of Bmi-1, Snail,
and ALDH1 in HNSCC patients could be a critical factor in
predicting disease progression and clinical outcomes.
4. Discussion
A recent study demonstrated that Bmi-1 mRNA and protein
overexpressed in a subpopulation of tumor initiating cells
in CD44+ HNSCC, which possessed self-renewal and tumor
formation ability [39]. Zhang et al. also reported that there
are side populations of oral squamous cell carcinomas that
express high levels of ABCG2, ABCB1, CD44, Oct-4, Bmi-
1, NSPc1, and CK19 [28]. Our previous work showed that
HNSCC-ALDH1+cellshavehighlevelsofBmi-1.Theability
to self-renew and radiochemoresistance were signiﬁcantly
suppressed in Bmi-1-silenced HNSCC-ALDH1+ cells [38].
Using microarray, western-blotting, and immunoﬂuorescentJournal of Oncology 9
Table 3: The expression proﬁling of up-regulated genes in ALDH1−/Bmi1-overexpressed as compared to ALDH1− HNSCC.
Probe set ID Gene symbol Gene title
217757 at A2M alpha-2-macroglobulin
209459 s at ABAT 4-aminobutyrate aminotransferase
213353 at ABCA5 ATP-binding cassette, sub-family A (ABC1), member 5
209993 at ABCB1(MDR1) ATP-binding cassette, sub-family B (MDR/TAP), member 1
214033 at ABCC6 ATP-binding cassette, sub-family C (CFTR/MRP), member 6
210246 s at ABCC8 ATP-binding cassette, sub-family C (CFTR/MRP), member 8
204567 s at ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1
209735 at ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2
204151 x at AKR1C1 aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1;
20-alpha (3-alpha)-hydroxysteroid dehydrogenase)
209699 x at AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile
acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III)
212224 at ALDH1A1 aldehyde dehydrogenase 1 family, member A1
204446 s at ALOX5 arachidonate 5-lipoxygenase
205216 s at APOH apolipoprotein H (beta-2-glycoprotein I)
39248 at AQP3 aquaporin 3 (Gill blood group)
218501 at ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3
219087 at ASPN Aspirin
201242 s at ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide
200921 s at BTG1 B-cell translocation gene 1, anti-proliferative
228067 at C2orf55 chromosome 2 open reading frame 55
206488 s at CD36 CD36 molecule (thrombospondin receptor)
208783 s at CD46 CD46 molecule, complement regulatory protein
1553970 s at CEL carboxyl ester lipase (bile salt-stimulated lipase)
203854 at CFI complement factor I
205043 at CFTR cystic ﬁbrosis transmembrane conductance regulator (ATP-binding cassette
sub-family C, member 7)
204260 at CHGB chromogranin B (secretogranin 1)
221188 s at CIDEB cell death-inducing DFFA-like eﬀector b
203953 s at CLDN3 claudin 3
221042 s at CLMN calmin (calponin-like, transmembrane)
1567081 x at CLN6 ceroid-lipofuscinosis, neuronal 6, late infantile, variant
208791 at CLU Clusterin
229831 at CNTN3 contactin 3 (plasmacytoma associated)
205615 at CPA1 carboxypeptidase A1 (pancreatic)
206212 at CPA2 carboxypeptidase A2 (pancreatic)
205509 at CPB1 carboxypeptidase B1 (tissue)
201117 s at CPE carboxypeptidase E
224829 at CPEB4 cytoplasmic polyadenylation element binding protein 4
204920 at CPS1 carbamoyl-phosphate synthetase 1, mitochondrial
201990 s at CREBL2 cAMP responsive element binding protein-like 2
205971 s at CTRB1 /// CTRB2 chymotrypsinogen B1 /// chymotrypsinogen B2
214411 x at CTRB2 chymotrypsinogen B2
209774 x at CXCL2 chemokine (C-X-C motif) ligand 2
205765 at CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5
228391 at CYP4V2 cytochrome P450, family 4, subfamily V, polypeptide 2
228739 at CYS1 cystin 1
222925 at DCDC2 doublecortin domain containing 210 Journal of Oncology
Table 3: Continued.
Probe set ID Gene symbol Gene title
205311 at DDC dopa decarboxylase (aromatic L-amino acid decarboxylase)
210397 at DEFB1 defensin, beta 1
221081 s at DENND2D DENN/MADD domain containing 2D
214787 at DENND4A DENN/MADD domain containing 4A
205684 s at DENND4C DENN/MADD domain containing 4C
214079 at DHRS2 dehydrogenase/reductase (SDR family) member 2
222850 s at DNAJB14 DnaJ (Hsp40) homolog, subfamily B, member 14
225415 at DTX3L deltex 3-like (Drosophila)
225645 at EHF Ets homologous factor
210080 x at ELA3A elastase 3A, pancreatic
201510 at ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-speciﬁc)
206191 at ENTPD3 ectonucleoside triphosphate diphosphohydrolase 3
220012 at ERO1LB ERO1-like beta (S. cerevisiae)
210103 s at FOXA2 forkhead box A2
235201 at FOXP2 forkhead box P2
226847 at FST Follistatin
205674 x at FXYD2 FXYD domain containing ion transport regulator 2
205890 s at GABBR1 /// UBD gamma-aminobutyric acid (GABA) B receptor, 1 /// ubiquitin D
205848 at GAS2 growth arrest-speciﬁc 2
216733 s at GATM glycine amidinotransferase (L-arginine:glycine amidinotransferase)
204965 at GC group-speciﬁc component (vitamin D binding protein)
219508 at GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type
225853 at GNPNAT1 glucosamine-phosphate N-acetyltransferase 1
212950 at GPR116 G protein-coupled receptor 116
212070 at GPR56 G protein-coupled receptor 56
203924 at GSTA1 glutathione S-transferase A1
221942 s at GUCY1A3 guanylate cyclase 1, soluble, alpha 3
228697 at HINT3 histidine triad nucleotide binding protein 3
209558 s at HIP1R huntingtin interacting protein 1 related
207062 at IAPP islet amyloid polypeptide
213620 s at ICAM2 intercellular adhesion molecule 2
203828 s at IL32 interleukin 32
205945 at IL6R interleukin 6 receptor
206598 at INS Insulin
226535 at ITGB6 integrin, beta 6
226189 at ITGB8 integrin, beta 8
210078 s at KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 1
219564 at KCNJ16 potassium inwardly-rectifying channel, subfamily J, member 16
205303 at KCNJ8 potassium inwardly-rectifying channel, subfamily J, member 8
212531 at LCN2 lipocalin 2
235970 at LCORL ligand dependent nuclear receptor corepressor-like
1554006 a at LLGL2 lethal giant larvae homolog 2 (Drosophila)
225996 at LONRF2 LON peptidase N-terminal domain and ring ﬁnger 2
242931 at LONRF3 LON peptidase N-terminal domain and ring ﬁnger 3
226748 at LYSMD2 LysM, putative peptidoglycan-binding, domain containing 2Journal of Oncology 11
Table 3: Continued.
Probe set ID Gene symbol Gene title
213975 s at LYZ lysozyme (renal amyloidosis)
222670 s at MAFB v-maf musculoaponeurotic ﬁbrosarcoma oncogene homolog B (avian)
223577 x at MALAT1 metastasis associated lung adenocarcinoma transcript 1 (non-protein coding)
220945 x at MANSC1 MANSC domain containing 1
204388 s at MAOA monoamine oxidase A
235077 at MEG3 maternally expressed 3
229254 at MFSD4 major facilitator superfamily domain containing 4
219797 at MGAT4A mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase,
isozyme A
204259 at MMP7 matrix metallopeptidase 7 (matrilysin, uterine)
227747 at MPZL3 myelin protein zero-like 3
204438 at MRC1 /// MRC1L1 mannose receptor, C type 1 /// mannose receptor, C type 1-like 1
203037 s at MTSS1 metastasis suppressor 1
212093 s at MTUS1 mitochondrial tumor suppressor 1
213693 s at MUC1 mucin 1, cell surface associated
213375 s at N4BP2L1 NEDD4 binding protein 2-like 1
220184 at NANOG Nanog homeobox
209107 x at NCOA1 nuclear receptor coactivator 1
1556057 s at NEUROD1 neurogenic diﬀerentiation 1
206915 at NKX2-2 N K 2h o m e o b o x2
225911 at NPNT Nephronectin
205259 at NR3C2 nuclear receptor subfamily 3, group C, member 2
212768 s at OLFM4 olfactomedin 4
203845 at PCAF p300/CBP-associated factor
240317 at PCDHB4 protocadherin beta 4
212593 s at PDCD4 programmed cell death 4 (neoplastic transformation inhibitor)
213228 at PDE8B phosphodiesterase 8B
225207 at PDK4 pyruvate dehydrogenase kinase, isozyme 4
205380 at PDZK1 PDZ domain containing 1
1553589 a at PDZK1IP1 PDZK1 interacting protein 1
226459 at PIK3AP1 phosphoinositide-3-kinase adaptor protein 1
220954 s at PILRB paired immunoglobulin-like type 2 receptor beta
219584 at PLA1A phospholipase A1 member A
206311 s at PLA2G1B phospholipase A2, group IB (pancreas)
221529 s at PLVAP plasmalemma vesicle associated protein
205912 at PNLIP pancreatic lipase
211766 s at PNLIPRP2 pancreatic lipase-related protein 2
208286 x at POU5F1(Oct4) P O Uc l a s s5h o m e o b o x1/ / /P O Uc l a s s5h o m e o b o x1 B/ / /P O Uc l a s s5
homeobox 1 pseudogene 3 /// POU class 5 homeobox 1 pseudogene 4
228469 at PPID Peptidylprolyl isomerase D (cyclophilin D)
210670 at PPY pancreatic polypeptide
242482 at PRKAR1A protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue speciﬁc
extinguisher 1)
227629 at PRLR Prolactin receptor
228656 at PROX1 prospero homeobox 1
205869 at PRSS1 protease, serine, 1 (trypsin 1)
205402 x at PRSS2 protease, serine, 2 (trypsin 2)12 Journal of Oncology
Table 3: Continued.
Probe set ID Gene symbol Gene title
213421 x at PRSS3 protease, serine, 3
203317 at PSD4 pleckstrin and Sec7 domain containing 4
203029 s at PTPRN2 protein tyrosine phosphatase, receptor type, N polypeptide 2
219562 at RAB26 RAB26, member RAS oncogene family
226436 at RASSF4 Ras association (RalGDS/AF-6) domain family member 4
223322 at RASSF5 Ras association (RalGDS/AF-6) domain family member 5
235638 at RASSF6 Ras association (RalGDS/AF-6) domain family member 6
204364 s at REEP1 receptor accessory protein 1
209752 at REG1A regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread
protein)
205886 at REG1B regenerating islet-derived 1 beta (pancreatic stone protein, pancreatic thread
protein)
205815 at REG3A regenerating islet-derived 3 alpha
1554003 at RGNEF Rho-guanine nucleotide exchange factor
219263 at RNF128 ring ﬁnger protein 128
221614 s at RPH3AL rabphilin 3A-like (without C2 domains)
213939 s at RUFY3 RUN and FYVE domain containing 3
210592 s at SAT1 spermidine/spermine N1-acetyltransferase 1
203408 s at SATB1 SATB homeobox 1
204035 at SCG2 secretogranin II (chromogranin C)
205697 at SCGN secretagogin, EF-hand calcium binding protein
229620 at SEPP1 Selenoprotein P, plasma, 1
202833 s at SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),
member 1
202376 at SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),
member 3
209443 at SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),
member 5
213572 s at SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1
227627 at SGK3 serum/glucocorticoid regulated kinase family, member 3
219256 s at SH3TC1 SH3 domain and tetratricopeptide repeats 1
204019 s at SH3YL1 SH3 domain containing, Ysc84-like 1 (S. cerevisiae)
213464 at SHC2 SHC (Src homology 2 domain containing) transforming protein 2
205799 s at SLC3A1 solute carrier family 3 (cystine, dibasic and neutral amino acid transporters,
activator of cystine, dibasic and neutral amino acid transport), member 1
223044 at SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1
228221 at SLC44A3 solute carrier family 44, member 3
213139 at SNAI2(Slug) snail homolog 2 (Drosophila)
1560228 at SNAI3(Snail) snail homolog 3 (Drosophila)
213721 at SOX2 SRY (sex determining region Y)-box 2
200795 at SPARCL1 SPARC-like 1 (mast9, hevin)
206239 s at SPINK1 serine peptidase inhibitor, Kazal type 1
213921 at SST somatostatin
216905 s at ST14 suppression of tumorigenicity 14 (colon carcinoma)
230285 at SVIP small VCP/p97-interacting protein
227134 at SYTL1 synaptotagmin-like 1
202286 s at TACSTD2 tumor-associated calcium signal transducer 2
205513 at TCN1 transcobalamin I (vitamin B12 binding protein, R binder family)
203887 s at THBD thrombomodulin
209937 at TM4SF4 transmembrane 4 L six family member 4
226403 at TMC4 transmembrane channel-like 4Journal of Oncology 13
Table 3: Continued.
Probe set ID Gene symbol Gene title
223503 at TMEM163 transmembrane protein 163
218345 at TMEM176A transmembrane protein 176A
220532 s at TMEM176B transmembrane protein 176B
200847 s at TMEM66 transmembrane protein 66
202687 s at TNFSF10 t u m o rn e c r o s i sf a c t o r( l i g a n d )s u p e r f a m i l y ,m e m b e r1 0
203824 at TSPAN8 tetraspanin 8
229169 at TTC18 tetratricopeptide repeat domain 18
209660 at TTR transthyretin (prealbumin, amyloidosis type I)
231008 at UNC5CL Unc-5 homolog C (C. elegans)-like
226344 at ZMAT1 zinc ﬁnger, matrin type 1
206059 at ZNF91 zinc ﬁnger protein 91
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Figure 5: Elimination of metastatic activity in HNSCC-ALDH1+cells treated with shBmi-1. (a) Summary of the in vivo metastasis ability
of diﬀerent numbers of HNSCC-ALDH1+, sh-Bmi-1 treated HNSCC-ALDH1+, HNSCC- ALDH1−, or Bmi-1-overexpressing HNSCC-
ALDH1− cellsexaminedbyxenotransplantationanalysis.(b)Theaveragenumbersofmetastaticfoci(leftpanel)andtotalweight(rightpanel)
inthelungsofmicetreatedwitheitherHNSCC-ALDH1+,sh-Bmi-1treatedHNSCC-ALDH1+,HNSCC-ALDH1−,orBmi-1-overexpressing
HNSCC-ALDH1−cells are shown. (∗P<. 05: ALDH1− versus Bmi-1-overexpressing ALDH1−; #P<. 05: ALDH1+ versus shBmi-1 treated
HNSCC-ALDH1+).
assays, Chen et al. conﬁrmed that ALDH1+-lineage cells
underwent epithelial-mesenchymal transition (EMT) and
endogenously co-expressed Snail [13]. In the current study,
our data demonstrated that HNSCC-ALDH1+ cells had high
levels of Bmi-1, at both the mRNA and protein levels (Fig-
ure 2). Using a lentiviral vector expressing shRNA targeting
Bmi-1, we observed that the level of ALDH1 expression and
tumorigenicpropertiesofHNSCC-ALDH1+ could be down-
regulated by knockdown of Bmi-1 (Figure 2). Importantly,
overexpression of Bmi-1 could turn HNSCC-ALDH1− into
cancer stem cell-like HNSCC-ALDH1+ cells (Figure 3).
Consistent with these ﬁndings, the immunohistochemical14 Journal of Oncology
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Figure 6: Coexpression of Bmi-1, Snail, and ALDH1 in HNSCC patient specimen and prediction of survival of the HNSCC patients. (a)
Representative pictures of triple positive (upper panel) and triple negative (lower panel) HNSCC cases. Coexpression of Bmi-1 and ALDH1
(b), Bmi-1 and Snail (c) or Snail and Bmi-1 (d) of 93 HNSCC patient samples were examined immunohistochemically. (e) Kaplan-Meier
analysis of overall survival of HNSCC patients according to expression of ALDH1 (+) Bmi-1 (+) Snail (+), ALDH1 (+) Bmi-1 (+) Snail (−),
ALDH1 (−) Bmi-1 (+) Snail (+) or ALDH1 (−)B m i - 1( −) Snail (−). (∗, P<. 05; ∗∗, P<. 01; ∗∗∗, P<. 001).
survey of 93 HNSCC patient tissues showed a positive cor-
relation between expression of Bmi-1, Snail, or ALDH1 and
tumor stage (Figure 6). Similar results were noted in other
malignancies [40]. Kaplan-Meier analysis demonstrated that
patients expressing Bmi-1, Snail, and ALDH1 were predicted
to have the worst survival prognosis of HNSCC patients
(Figure 6(e)). However, a recent study showed a signiﬁcant
correlation between negative Bmi-1 protein expression and
the recurrence of tongue cancer. Their results showed Snail
and c-myc expression did not correlate with prognosis
[41] .T h ed i v e r g e n c ef r o mo u rr e s u l t sm a yb ed u et o
the diﬀerent pathophysiology of HNSCC. Most HNSCC
patients in Taiwan consume alcohol, chew betel quid and
smoke cigarettes. Tongue cancer patients, especially female
tongue cancer patients, usually do not have these habits [3].
The close relationship between tongue cancer and human
papillomavirus has been explored by many researchers [42–
45]. The correlation between cancer stem cells and the virus
infection remains to be discovered.
The prognosis of HNSCC patients with distant metas-
tases in the lung, liver, and bone is very poor [3, 46]. In this
study, we found that Bmi-1 can regulate Snail and ALDH1;Journal of Oncology 15
change the EMT-related genotypes of the ALDH1− cells;
and modulate distant lung metastases (Figure 5). Distant
metastases have been reported to be associated with Bmi-1
expression in breast cancer [47–49], melanoma [50], gastric
cancer [51], and colon cancer [30]. Microarray analysis
revealed that eleven gene signatures, which were correlated
to the Bmi-1-driven pathway, were closely related to distant
lung metastases [40]. Bmi-1 is the target gene of SALL4 in
human hematopoietic as well as leukemic cells and is down-
regulated if SALL4 is knocked down by the siRNA in the HL-
60 leukemia cell line [52, 53]. Recently, researchers employed
microRNA proﬁling to gain insight into the role of Bmi-1 in
regulatingEMT.OverexpressionofmiR-200cdecreasedBmi-
1 expression in breast cancer stem cells (BCSCs) and inhib-
i t e dt h ef o r m a t i o no fm a m m a r yd u c t sa sw e l la st u m o r sb y
normal mammary stem cells and BCSCs [54]. Bhattacharya
et al. found that miR-15a and miR-16 directly targeted the
Bmi-1 3  untranslated region and correlated with Bmi-1
protein levels in ovarian cancer patients and cell lines [55].
Further research eﬀort is needed in this area. Together, our
research shows that the Bmi-1 signaling pathways play a
majorroleinthemaintenanceofstemnessandthemetastatic
ability of HNSCC-CSC by regulating of Snail expression.
Additionally, we demonstrate coexpression of Bmi-1, Snail,
and ALDH1 in HNSCC patients was positively correlated
with tumor grade and the worst prognosis.
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